ArticleEBioMedicine2015
Linezolid for Treating Tuberculosis: A Delicate Balancing Act.
Article in EBioMedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Linezolid for drug-resistant pulmonary tuberculosis.The Cochrane database of systematic reviews · 2019Pooled it
- Engineering of OHet72 Nanocrystals into Nanostructured Microparticles for Pulmonary Delivery of a Novel Antitubercular Drug Candidate.Pharmaceutics · 2026Article
- Single Saliva Sample Linezolid Dosing for Multidrug-Resistant Tuberculosis: A Population Pharmacokinetic Modelling of Plasma and Saliva.Clinical pharmacokinetics · 2026Article
- Relapse and Emergent Resistance With Novel Short-Course Regimens for Multidrug-Resistant Tuberculosis, United States, 2022-2024.Open forum infectious diseases · 2026Article
- A Tandem Ring Closure and Nitrobenzene Reduction with Sulfide Provides an Improved Route to an Important Intermediate for the Anti-Tuberculosis Drug Candidate Sutezolid.Organic process research & development · 2024Article
- The Pharmacokinetics of CPZEN-45, a Novel Anti-Tuberculosis Drug, in Guinea Pigs.Pharmaceutics · 2023Article
- Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis.Pharmaceutics · 2022Article
- Pharmacokinetic analysis of linezolid for multidrug resistant tuberculosis at a tertiary care centre in Mumbai, India.Frontiers in pharmacology · 2022Article
- Repurposing Immunomodulatory Drugs to Combat Tuberculosis.Frontiers in immunology · 2021Review
- Epidemiological cut-offs for Sensititre susceptibility testing of Mycobacterium tuberculosis: interpretive criteria cross validated with whole genome sequencing.Scientific reports · 2020Article
- Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.PLoS medicine · 2019Observational
- Linezolid: a review of its properties, function, and use in critical care.Drug design, development and therapy · 2018Review
- Microbiological profile and antibiotic susceptibility pattern of Gram-positive isolates at a tertiary care hospital.Journal of laboratory physiciansArticle
Corrections and comments
- Comment on
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.